Aquestive Therapeutics Inc. Insider Trading

AQST

Last 12 months

Insiders sold $2.39M and bought nothing on the open market.

31% of the selling was scheduled in advance under 10b5-1 plans. President and CEO Daniel Barber sold 753K on Mar 10, 15% of their stake, outside a plan. The last open-market buy by an executive or director was in Jun 2022.

Net open-market

−$2.39M

0 buys · 15 sales

Under a 10b5-1 plan

31%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Jun 2022

Jun 14, 2022

Get an email when AQST's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 15	Daniel Barber President and CEO	Sold10b5-1 plan	25,000	$4.22	106K	3.8%	Form 4
Sep 15	Daniel Barber President and CEO	Sold10b5-1 plan	25,000	$4.82	121K	3.7%	Form 4
Sep 9	Sherry Korczynski Chief Commercial Officer	Sold10b5-1 plan	8,750	$5.22	46K	3.6%	Form 4
Aug 17	Daniel Barber President and CEO	Sold10b5-1 plan	25,000	$4.29	107K	4.1%	Form 4
Jul 15 – 16	Daniel Barber President and CEO	Sold10b5-1 plan 2 parts	25,000	$4.01 average	100K	3.9%	Form 4
Jun 23	Julie Krop Director	Sold10b5-1 plan	25,000	$5.02	126K	100%	Form 4
Jun 15	Daniel Barber President and CEO	Sold10b5-1 plan	25,000	$4.16	104K	3.8%	Form 4
May 15	Daniel Barber President and CEO	Sold10b5-1 plan	8,257	$4.29	35K	1.2%	Form 4
Mar 10	Peter E. Boyd Chief People Officer	SoldNo plan	29,814	$4.17	124K	8.1%	Form 4
Mar 10	Daniel Barber President and CEO	SoldNo plan	180,677	$4.17	753K	15%	Form 4
Mar 10	Lori J Braender Chief Legal Officer	SoldNo plan	40,102	$4.17	167K	8.3%	Form 4
Mar 10	Melina Cioffi SVP, Regulatory Affairs	SoldNo plan	25,311	$4.17	106K	8.4%	Form 4
Mar 10	A Ernest Toth Jr Chief Financial Officer	SoldNo plan	58,254	$4.17	243K	13%	Form 4
Mar 10	Sherry Korczynski Chief Commercial Officer	SoldNo plan	15,741	$4.17	66K	6.1%	Form 4
Mar 10	Cassie Jung Chief Operating Officer	SoldNo plan	45,791	$4.17	191K	14%	Form 4
Oct 15, 2025	Cassie Jung Chief Operating Officer	Sold10b5-1 plan	67,575	$7.01	474K	22%	Form 4
Oct 15, 2025	Carl N Kraus Chief Medical Officer	Sold10b5-1 plan	20,272	$7.00	142K	6.7%	Form 4
Oct 15, 2025	Peter E. Boyd See Remarks	Sold10b5-1 plan	10,000	$7.00	70K	3.6%	Form 4
Sep 26, 2025	Daniel Barber President and CEO	Sold10b5-1 plan	91,343	$6.03	551K	9.0%	Form 4
Sep 26, 2025	Peter E. Boyd See Remarks	Sold10b5-1 plan	10,000	$6.30	63K	3.5%	Form 4
Sep 19, 2025	Daniel Barber President and CEO	Sold10b5-1 plan	400	$6.00	2K	<0.1%	Form 4
Sep 5, 2025	Peter E. Boyd See Remarks	Sold10b5-1 plan	15,000	$5.30	80K	4.9%	Form 4
Sep 4, 2025	Cassie Jung Chief Operating Officer	Sold10b5-1 plan	62,180	$5.00	311K	18%	Form 4
Nov 26, 2024	Cassie Jung Chief Operating Officer	SoldNo plan	44	$4.87	$214	<0.1%	Form 4

Oct 1510b5-1 plan
Daniel Barber
President and CEO · sold 25,000 at $4.22
106K
3.8% of stake
Sep 1510b5-1 plan
Daniel Barber
President and CEO · sold 25,000 at $4.82
121K
3.7% of stake
Sep 910b5-1 plan
Sherry Korczynski
Chief Commercial Officer · sold 8,750 at $5.22
46K
3.6% of stake
Aug 1710b5-1 plan
Daniel Barber
President and CEO · sold 25,000 at $4.29
107K
4.1% of stake
Jul 15 – 1610b5-1 plan
Daniel Barber
President and CEO · sold 25,000 at avg $4.01
100K
3.9% of stake
Jun 2310b5-1 plan
Julie Krop
Director · sold 25,000 at $5.02
126K
100% of stake
Jun 1510b5-1 plan
Daniel Barber
President and CEO · sold 25,000 at $4.16
104K
3.8% of stake
May 1510b5-1 plan
Daniel Barber
President and CEO · sold 8,257 at $4.29
35K
1.2% of stake
Mar 10No plan
Peter E. Boyd
Chief People Officer · sold 29,814 at $4.17
124K
8.1% of stake
Mar 10No plan
Daniel Barber
President and CEO · sold 180,677 at $4.17
753K
15% of stake
Mar 10No plan
Lori J Braender
Chief Legal Officer · sold 40,102 at $4.17
167K
8.3% of stake
Mar 10No plan
Melina Cioffi
SVP, Regulatory Affairs · sold 25,311 at $4.17
106K
8.4% of stake
Mar 10No plan
A Ernest Toth Jr
Chief Financial Officer · sold 58,254 at $4.17
243K
13% of stake
Mar 10No plan
Sherry Korczynski
Chief Commercial Officer · sold 15,741 at $4.17
66K
6.1% of stake
Mar 10No plan
Cassie Jung
Chief Operating Officer · sold 45,791 at $4.17
191K
14% of stake
Oct 15, 202510b5-1 plan
Cassie Jung
Chief Operating Officer · sold 67,575 at $7.01
474K
22% of stake
Oct 15, 202510b5-1 plan
Carl N Kraus
Chief Medical Officer · sold 20,272 at $7.00
142K
6.7% of stake
Oct 15, 202510b5-1 plan
Peter E. Boyd
See Remarks · sold 10,000 at $7.00
70K
3.6% of stake
Sep 26, 202510b5-1 plan
Daniel Barber
President and CEO · sold 91,343 at $6.03
551K
9.0% of stake
Sep 26, 202510b5-1 plan
Peter E. Boyd
See Remarks · sold 10,000 at $6.30
63K
3.5% of stake
Sep 19, 202510b5-1 plan
Daniel Barber
President and CEO · sold 400 at $6.00
2K
<0.1% of stake
Sep 5, 202510b5-1 plan
Peter E. Boyd
See Remarks · sold 15,000 at $5.30
80K
4.9% of stake
Sep 4, 202510b5-1 plan
Cassie Jung
Chief Operating Officer · sold 62,180 at $5.00
311K
18% of stake
Nov 26, 2024No plan
Cassie Jung
Chief Operating Officer · sold 44 at $4.87
$214
<0.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AQST, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with AQST

CompareIntrinsic value

XOMAXOMA Corporation

€0.05-3.60%64

CTNMContineum Therapeutics, Inc.

$9.79+1.03%10

KALVKalVista Pharmaceuticals Inc.

No recent price25

SPROSpero Therapeutics Inc.

$1.07+2.88%63

BFRIBiofrontera Inc.

$0.90+1.55%30

OCULOcular Therapeutix Inc.

$7.14+4.69%10

CARMCarisma Therapeutics Inc.

$0.00+100.00%60

GOSSGossamer Bio Inc.

$9.40+1.29%10

Held by ETFs

AQST is in 11 US ETFs. The largest of them, with AQST's weight in each:

Spot a number that looks wrong? Check it in AQST's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AQST

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.